In the latest of its deals focusing on strengthening its dermatology portfolio, LEO Pharma has in-licensed PellePharm’s patidegib, an orphan drug currently under development for the prevention and treatment of Gorlin Syndrome, also known as nevoid basal cell carcinoma (BCC) syndrome. Patidegib is a hedgehog pathway inhibitor that down-regulates a key component in tumour cell division. Data from Phase II trials suggest the therapy is effective in treating BCCs with minimal side effects and a Phase III trial is expected to commence in the first quarter of 2019.